Can animal models resemble a premenstrual dysphoric condition?

Front Neuroendocrinol. 2022 Jul:66:101007. doi: 10.1016/j.yfrne.2022.101007. Epub 2022 May 25.

Abstract

Around 80% of women worldwide suffer mild Premenstrual Disorders (PMD) during their reproductive life. Up to a quarter are affected by moderate to severe symptoms, and between 3% and 8% experience a severe form. It is classified as premenstrual syndrome (PMS) with predominantly physical symptoms and premenstrual dysphoric disorder (PMDD) with psychiatric symptoms. The present review analyzes the factors associated with PMD and the Hypothalamus-Pituitary-Ovarian or Hypothalamus-Pituitary-adrenal axis and discusses the main animal models used to study PMDD. Evidence shows that the ovarian hormones participate in PMDD symptoms, and several points of regulation of their synthesis, metabolism, and target sites could be altered. PMDD is complex and implies several factors that require consideration when this condition is modeled in animals. Of particular interest are those points related to areas that may represent opportunities to develop new approximations to understand the mechanisms involved in PMDD and possible treatments.

Keywords: Allopregnanolone; Animal models; Estrous cycle; GABAAR; HPA axis; Menstrual cycle; Premenstrual disorders; Progesterone.

Publication types

  • Review

MeSH terms

  • Animals
  • Female
  • Humans
  • Hypothalamo-Hypophyseal System / metabolism
  • Models, Animal
  • Pituitary-Adrenal System / metabolism
  • Premenstrual Dysphoric Disorder*
  • Premenstrual Syndrome* / diagnosis
  • Premenstrual Syndrome* / metabolism
  • Premenstrual Syndrome* / psychology